Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma
Paludo J, Dueck A, Bhatnagar V, Brown A, Cathcart-Rake E, Copley D, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Power B, Ritchie J, Ross J, Ruddy K, Schellhorn S, Tarver M, Torre L, Wood W, Gross C, Kluetz P, Thanarajasingam G. Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma. Blood 2024, 144: 387-387. DOI: 10.1182/blood-2024-194607.Peer-Reviewed Original ResearchEastern Cooperative Oncology GroupPhysical functionPatient reportsTreatment toleranceCompletion ratesBaseline 6MWTExit surveyInterquartile rangeAssess treatment tolerancePost-treatment follow-upAssessment of PFCooperative Oncology GroupMedian wear timeUnique implementation challengesWearable sensor dataWalk testCytotoxic chemotherapyNon-Hispanic/LatinoNo standard approachOncology GroupAlaska NativesPerformance statusPF measuresFull-time employmentMedian timeIntegrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study.
Thanarajasingam G, Dueck A, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Paludo J, Power B, Ross J, Ruddy K, Schellhorn S, Tarver M, Wood W, Gross C, Kluetz P. Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study. Journal Of Clinical Oncology 2024, 42: 1564-1564. DOI: 10.1200/jco.2024.42.16_suppl.1564.Peer-Reviewed Original ResearchPhysical functionPF measuresDaily stepsClinically meaningful change scoresAverage daily stepsEvaluate physical functionDigital health studiesMeasures of PFWearable dataHealth StudyWalk testWeekend daysCore outcomeChange scoresPerformance statusTreatment toleranceDetect changesPearson correlationECOG performance statusBreast cancerEvaluate feasibilityCancer trialsSignificant declineData collectionBaselineImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate